Targeting fibronectin for cancer imaging and therapy
- 1 December 2016
- journal article
- review article
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 5 (4) , 639-654
Abstract
During cancer progression, the extracellular matrix (ECM) undergoes dramatic changes, which promote cancer cell migration and invasion. In the remodeled tumor ECM, the fibronectin (FN) level is upregulated to assist tumor growth, progression, and invasion. FN serves as a central organizer of ECM molecules and mediates the crosstalk between the tumor microenvironment and cancer cells. Its upregulation is correlated with angiogenesis, cancer progression, metastasis, and drug resistance. A number of FN-targeting ligands have been developed for cancer imaging and therapy. Thus far, FN-targeting imaging agents have been tested for nuclear imaging, MRI, and fluorescence imaging, and for tumor detection and localization. FN-targeting therapeutics, including nuclear medicine, chemotherapy drugs, cytokines, and photothermal moieties, were also developed for cancer therapy. Because of the prevalence of FN overexpression in cancer, FN targeting imaging agents and therapeutics have the promise of broad applications in the diagnosis, treatment, and image-guided interventions of many types of cancers. This review will summarize the current understanding of the role of FN in cancer, discuss the design and development of FN-targeting agents, and highlight the applications of these FN-targeting agents in cancer imaging and therapy.Keywords
Funding Information
- National Cancer Institute (R01 CA194518)
This publication has 137 references indexed in Scilit:
- Induction of epithelial‐mesenchymal transition with O‐glycosylated oncofetal fibronectinFEBS Letters, 2012
- High-Yielding Aqueous 18F-Labeling of Peptides via Al18F ChelationBioconjugate Chemistry, 2011
- Synthesis and Evaluation of Nanoglobular Macrocyclic Mn(II) Chelate Conjugates as Non-Gadolinium(III) MRI Contrast AgentsBioconjugate Chemistry, 2011
- A novel human fibronectin cryptic sequence unmasked by the insertion of the angiogenesis‐associated extra type III domain BInternational Journal of Cancer, 2009
- 124I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of 131I-L19-SIP radioimmunotherapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- Hypoxia-Induced Lysyl Oxidase Is a Critical Mediator of Bone Marrow Cell Recruitment to Form the Premetastatic NicheCancer Cell, 2009
- A Peptide Targeted Contrast Agent Specific to Fibrin-Fibronectin Complexes for Cancer Molecular Imaging with MRIBioconjugate Chemistry, 2008
- The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem CellsCell, 2008
- Systemic Spread Is an Early Step in Breast CancerCancer Cell, 2008
- Multiple cardiovascular defects caused by the absence of alternatively spliced segments of fibronectinDevelopmental Biology, 2007